Plexision

Executive Summary

Plexision is a Pittsburgh-based biotechnology company specializing in cellular biomarker-based diagnostic tests for personalized medicine, primarily targeting solid organ transplantation and immunological disorders. Since its founding in 2018, the company has established a CLIA-certified laboratory and developed a portfolio that includes FDA-approved and lab-developed tests designed to predict transplant rejection and quantify cellular immunity to viral infections such as CMV and SARS-CoV-2. By enabling more precise monitoring of immune status, Plexision aims to improve patient outcomes and reduce the need for invasive biopsies. Despite being a private company with limited publicly available financial data, its approved products and focus on high-need areas in transplantation position it as a niche player in the diagnostics space. The company's technology addresses critical gaps in post-transplant care and infectious disease management, offering potential for steady commercial growth as adoption increases among transplant centers.

Upcoming Catalysts (preview)

• H2 2026FDA Approval for Expanded Test Menu (e.g., CMV Immunity Monitoring)60% success
• Q3 2026Strategic Partnership with Major Transplant Center or Hospital Network70% success
• Q4 2026Publication of Clinical Validation Data for SARS-CoV-2 T-Cell Immunity Test80% success